Trial Profile

The Effect of Repeat Dosing of Imlunestrant on CYP3A Activity in Healthy Women of Non-childbearing Potential

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imlunestrant (Primary) ; Midazolam (Primary)
Indications Breast cancer; Endometrial cancer; HER2 negative breast cancer
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

12 Jan 2023 Status changed from active, no longer recruiting to completed.
26 Dec 2022 Planned End Date changed from 9 Dec 2022 to 23 Dec 2022.
26 Dec 2022 Planned primary completion date changed from 9 Dec 2022 to 23 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com